v3.26.1
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
   
Six months ended
June 30
    
Three months ended
June 30
  
   
2026
    
2025
    
2026
    
2025
  
Clinical trials and other payments to R&D-related service providers
  
$
2,429
    
$
598
    
$
1,538
    
$
442
  
R&D payroll and related expenses, other than share-based compensation
    
774
      
854
      
511
      
485
  
R&D share-based compensation expenses
    
230
      
-
      
100
      
-
  
G&A payroll and related expenses, other than share-based compensation
    
661
      
739
      
420
      
407
  
G&A share-based compensation expenses
    
312
      
58
      
97
      
37
  
Professional services
    
1,571
      
1,111
      
788
      
586
  
Depreciation expenses
    
5
      
7
      
3
      
3
  
Other segment expenses (*)
    
447
      
567
      
223
      
324
  
Operating loss
    
6,429
      
3,934
      
3,680
      
2,284
  
Interest income
    
(46
)
    
(46
)
    
(14
)
    
(44
)
Interest expense
    
-
      
11
      
-
      
-
  
Other financing expense (income), net
    
(99
)
    
336
      
(115
)
    
260
  
Income taxes
      
**
    
3
        
**
    
3
  
Net loss
  
$
6,284
    
$
4,238
    
$
3,551
    
$
2,503
  
                                 
Segment assets
  
$
4,246
    
$
5,797
    
$
4,246
    
$
5,797
  
Expenditures for segment assets
  
$
-
    
$
(7
)
  
$
-
    
$
-
  
Segment liabilities
  
$
4,202
    
$
5,677
    
$
4,202
    
$
5,677
  
 
  (*)
Other segment expenses include mainly general and administrative-related expenses, such as rent and maintenance expenses, travel and HR expenses.
  (**)
Represents an amount less than $1